Logotype for Beam Therapeutics Inc

Beam Therapeutics (BEAM) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Beam Therapeutics Inc

Q3 2026 earnings summary

3 Nov, 2026

Executive summary

  • Q3 net loss widened to $134.4M from $112.6M year over year as revenue fell and operating expenses rose; BEAM-302 and BEAM-301 reported encouraging efficacy signals.

  • Cash, cash equivalents and marketable securities totaled $1.044B at September 30, 2026; runway is expected into mid-2029, subject to conditions on additional borrowings.

  • Clinical progress spanned BEAM-302, BEAM-301, BEAM-304 and risto-cel, with a potential U.S. BLA filing for risto-cel as early as year-end 2026.

Financial highlights

  • Q3 license and collaboration revenue was $0.3M versus $9.7M; R&D expense was $110.1M versus $109.8M and G&A was $31.5M versus $26.7M year over year.

  • Q3 operating loss was $141.3M versus $126.8M; net loss was $134.4M, or $1.28 per share, versus $112.6M, or $1.10 per share.

  • 9M revenue was $32.5M versus $25.6M, primarily reflecting a $25.0M Lilly milestone; operating expenses were $407.6M versus $391.9M and net loss was $351.4M versus $323.0M.

  • 9M operating cash use was $305.4M versus $261.8M; cash, cash equivalents and restricted cash ended at $220.0M.

Outlook and guidance

  • Updated risto-cel data and a U.S. BLA submission are expected by year-end 2026, with filing possible as early as year-end.

  • BEAM-302 pivotal-cohort dosing is expected to complete in H1 2027; its Phase 1/2 trial is designed to support a potential U.S. accelerated approval path.

  • BEAM-304 Phase 1/2 dosing is expected to begin in early 2027, initially targeting patients with the R408W mutation in PKU.

  • Cash and marketable securities are expected to fund operations and planned development into mid-2029, including $200M expected from the Sixth Street facility subject to borrowing conditions.

  • BEAM-301 enrollment is proceeding in a 60 mg cohort, with FDA discussions planned on a potential regulatory approval path.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Beam Therapeutics